{"ok":true,"trend":{"id":408226,"platform":"x","region":"SE","key":"retatrutide trial shows up to 25% weight loss in phase 3 study","title":"Retatrutide Trial Shows Up to 25% Weight Loss in Phase 3 Study","url":"https://x.com/search?q=Retatrutide%20Trial%20Shows%20Up%20to%2025%25%20Weight%20Loss%20in%20Phase%203%20Study&src=trend_click","first_seen":"2026-09-29T22:08:27.248659Z","last_seen":"2026-09-29T22:53:26.965786Z","last_rank":33,"peak_rank":32,"last_volume":304,"peak_volume":304,"seen_count":4,"score":0.6184375,"category_hint":"Trending now","section":null,"category":null,"summary":"Eli Lilly's obesity drug retatrutide delivered weight loss of up to 25% in a Phase 3 clinical trial, according to reported results. The injectable, which targets multiple hormone receptors, is being positioned as a potential rival to tirzepatide and semaglutide in the fast-growing weight-loss drug market, drawing attention from patients and analysts.","why":"New Phase 3 results suggest a potential next-generation obesity treatment, fueling interest in the booming weight-loss drug race.","tone":"positive","entities":["Eli Lilly","Retatrutide"],"summarized_at":"2026-09-29T22:10:36.140171Z","meta":{"lang":"en","explore":true},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"Retatrutide Phase 3 Trial Shows Up to 25% Weight Loss","timeline":[{"captured_at":"2026-09-29T22:08:27.248659Z","rank":33,"volume":103},{"captured_at":"2026-09-29T22:23:27.240320Z","rank":32,"volume":187},{"captured_at":"2026-09-29T22:38:33.949248Z","rank":33,"volume":222},{"captured_at":"2026-09-29T22:53:26.965786Z","rank":33,"volume":304}],"posts":[],"elsewhere":[],"window":"7d"}}